Bevacizumab for ophthalmic diseases

被引：2
|
作者：
Michels, Stephan [1 ]
Prager, Franz [1 ]
Bakri, Sophie J. [2 ]
Wacht, Joachim [3 ]
机构：
[1] Med Univ Vienna, Gen Hosp Vienna, Dept Ophthalmol, Wahringer Gurtel 18-20, Vienna, Wien 1090, Austria
[2] Dept Ophthalmol, Rochester, MN 55905 USA
[3] Dept Ophthalmol, Berlin, Germany
来源：
EXPERT REVIEW OF OPHTHALMOLOGY | 2007年 / 2卷 / 03期
关键词：
AMD; angiogenesis; anti-VEGF; Avastin ((R)); bevacizumab; choroidal neovascularization; eye; macular degeneration; neovascularization; ocular; vascular endothelial growth factor;
D O I：
10.1586/17469899.2.3.369
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Bevacizumab, a humanized monoclonal antibody that binds to all isoforms of vascular endothelial growth factor, was originally developed to inhibit tumor angiogenesis. Following its approval for the treatment of metastatic colorectal cancer, bevacizumab was initially used systemically in patients with neovascular age-related macular degeneration. Two case reports on intravitreal bevacizumab led to numerous clinical and preclinical studies on bevacizumab. Intravitreal bevacizumab is popular worldwide as an inexpensive off-label treatment for several neovascular ocular diseases. This article reviews the current clinical and preclinical studies using bevacizumab in ophthalmology.
引用
收藏
页码：369 / 378
页数：10
相关论文
共 50 条
  • [41] Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer
    Kapelakis, Ioannis
    Toutouzas, Konstantinos
    Drakopoulou, Maria
    Michelongona, Archontoula
    Zagouri, Flora
    Mpamias, Aristotle
    Pliatsika, Paraskevi
    Dimopoulos, Meletios-Athanasios
    Stefanadis, Christodoulos
    Tousoulis, Dimitrios
    HELLENIC JOURNAL OF CARDIOLOGY, 2017, 58 (03) : 215 - 219
  • [42] Efficacy of intravitreal bevacizumab to treat retinal angiomatous proliferation stage II and III
    Montero, Javier A.
    Fernandez, Maria I.
    Gomez-Ulla, Francisco
    Ruiz-Moreno, Jose M.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2009, 19 (03) : 448 - 451
  • [43] Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
    David A. Reardon
    Annick Desjardins
    Katherine B. Peters
    Sridharan Gururangan
    John H. Sampson
    Roger E. McLendon
    James E. Herndon
    Anuradha Bulusu
    Stevie Threatt
    Allan H. Friedman
    James J. Vredenburgh
    Henry S. Friedman
    Journal of Neuro-Oncology, 2012, 107 : 155 - 164
  • [44] Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases
    Quan Dong Nguyen
    De Falco, Sandro
    Behar-Cohen, Francine
    Lam, Wai-Ching
    Li, Xuri
    Reichhart, Nadine
    Ricci, Federico
    Pluim, Jennifer
    Li, William W.
    ACTA OPHTHALMOLOGICA, 2018, 96 (01) : E1 - E9
  • [45] Bevacizumab treatment of prostate cancer
    Small, Alexander C.
    Oh, William K.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (09) : 1241 - 1249
  • [46] Topical bevacizumab treatment in aniridia
    Lapid-Gortzak, Ruth
    Santana, Nathalie T. Y.
    Nieuwendaal, Carla P.
    Mourits, Maarten P.
    van der Meulen, Ivanka J. E.
    INTERNATIONAL OPHTHALMOLOGY, 2018, 38 (04) : 1741 - 1746
  • [47] Subconjunctival bevacizumab for corneal neovascularization
    Zaki, Ahmed A.
    Farid, Samar F.
    ACTA OPHTHALMOLOGICA, 2010, 88 (08) : 868 - 871
  • [48] Bevacizumab for eye diseases - Legal, regulatory, and ethical overview
    Jose, Vinu
    Radhakrishna, Swetha
    Pipalava, Parag
    Singh, Inderjeet
    INDIAN JOURNAL OF PHARMACOLOGY, 2019, 51 (06) : 377 - 383
  • [49] Combined intravitreal bevacizumab and photodynamic therapy for neovascular age-related macular degeneration
    Markus S. Ladewig
    Stefanie E. Karl
    Victoria Hamelmann
    Hans-Martin Helb
    Hendrik P. N. Scholl
    Frank G. Holz
    Nicole Eter
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2008, 246 : 17 - 25
  • [50] Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    Reardon, David A.
    Desjardins, Annick
    Peters, Katherine B.
    Vredenburgh, James J.
    Gururangan, Sridharan
    Sampson, John H.
    McLendon, Roger E.
    Herndon, James E., II
    Coan, April
    Threatt, Stevie
    Friedman, Allan H.
    Friedman, Henry S.
    CANCER, 2011, 117 (23) : 5351 - 5358
12345